In the next few years, it may be difficult for MSD to meet its competitors

[China Pharmaceutical network enterprise news] at present, two PD-1 products have been listed in China, namely, Squibb's drug O and MSD's drug K The "OK" debate is huge After fierce competition, the impressive performance of MSD's K drug with a growth rate of 89% over the same period of US $1.67 billion exceeded that of Squibb's o drug with a sales volume of US $1.63 billion (a growth rate of 36% over the same period), and officially completed the overtaking in the corner It is worth mentioning that at present, MSD has become the focus of pharmaceutical enterprises in various countries So, how does this leading pharmaceutical company do it? According to the published data, the author made a brief anatomy In terms of time sequence, Merck and Sadong company merged in 1953, and their scientific research and sales advantages complement each other The company is called Merck in the United States and Canada, and Merck in other regions In terms of research investment, MSD has always been highly willing to "spend money" As early as 1992, the R & D investment of MSD has exceeded US $1 billion In 2017, the R & D investment of the company reached US $10.2 billion, an increase of almost 10 times In terms of acquisition enhancement, in 2013, MSD acquired idenix, oncoethix, cubist and other companies to strengthen its strength in the fields of hepatitis C, cancer and antibiotics Correct values: in terms of manufacturing, we adhere to the value of "drugs are produced for human beings, not for profit" In 1987, mosadong successfully developed ivermectin to fight against river blindness, and announced to donate ivermectin free of charge until the disease was eliminated in the world, making a great contribution to the global patients with such diseases Today, MSD has established a century old business in the world With the help of prescription drugs, vaccines and biological products and animal health products, it works closely with all parties to provide innovative medical solutions for more than 140 markets around the world Clear market layout In terms of the business layout of MSD in China, in 1992, MSD entered China In addition to prescription medicine business, MSD also includes animal health business in China Veterinary products involve many fields such as disease prevention, treatment and control of livestock, poultry and pets MSD is committed to protecting and caring for animal health and human health Among them, in terms of prescription drugs and vaccine products, currently, MSD provides more than 40 kinds of human drugs and vaccines in China, covering cancer, cardiovascular, anti infection, male health, female health, orthopedics, pain, skin, respiration, diabetes, specialty drugs and other fields In terms of animal health products, MSD provides nearly 40 kinds of animal health products to the Chinese market to prevent, treat and control diseases of poultry and pets At present, MSD is at the forefront of research and development with its strength, and is committed to research on cancer, cardiovascular metabolic diseases, emerging animal diseases, Alzheimer's disease, infectious diseases such as HIV and Ebola virus, and promote their prevention and treatment Products crush competitors In 2018, three phase III clinical studies from MSD showed that keytruda, the cancer immunotherapy of MSD, has prolonged the survival period compared with standard nursing chemotherapy in the first-line treatment of lung cancer, and its competitors have been frustrated one after another In addition, MSD has won the first-line lung cancer indications, which will make MSD occupy an obvious dominant position in the large oncology market of lung cancer According to industry data, keytruda's global sales in 2017 were $3.8 billion With its strong R & D strength, correct values and heavyweight products, MSD has been listed on the wealth list for many years On June 7, 2017, the 2017 Fortune 500 ranking was released, and MSD ranked 69th; on July 19, 2018, the Fortune 500 ranking was released, and MSD ranked 276 The industry believes that in the next few years, MSD may be difficult to meet competitors.